Skip to main content
Joseph Rosenthal, MD, Pediatric Hematology & Oncology, Duarte, CA, City of Hope Comprehensive Cancer Center

JosephRosenthalMD

Pediatric Hematology & Oncology Duarte, CA

Director, Pediatric Hematology/Oncology

Dr. Rosenthal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rosenthal's full profile

Already have an account?

Education & Training

  • University of California (Irvine)/Children's Hospital of Orange County
    University of California (Irvine)/Children's Hospital of Orange CountyFellowship, Pediatric Hematology/Oncology, 1993 - 1996
  • University of Colorado
    University of ColoradoFellowship, Pediatric Hematology/Oncology, 1988 - 1991
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 1983

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2024 - 2025
  • CA State Medical License
    CA State Medical License 1956 - 2025
  • WY State Medical License
    WY State Medical License 1990 - 1994
  • CO State Medical License
    CO State Medical License 1991 - 1993
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
    Joseph Rosenthal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Life-Changing Transplant Gives Sickle Cell Patient a Second Chance
    Life-Changing Transplant Gives Sickle Cell Patient a Second ChanceOctober 3rd, 2018
  • City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaApril 13th, 2018
  • Promising Sickle Cell Research Gets Nearly $6MM Boost from CIRM
    Promising Sickle Cell Research Gets Nearly $6MM Boost from CIRMMarch 22nd, 2018
  • Join now to see all

Professional Memberships

  • Hematology Research Laboratory, Soroka Medical Center
    Member

Other Languages

  • Hebrew

Hospital Affiliations